Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Peter Clark, MA, MD, FRCP: A Payer Perspective

Varsha Gandhi, PhD, on Ibrutinib

Advertisement

Advertisement




Jul
22
Today In Oncology
Integrating Environmental Health Into Pediatric Cancer Care May Improve Outcomes
Emergency Department Cancer Diagnosis Associated With Higher Mortality Across 16 Cancer Types
AMP Recognizes NCI Pathologist With Award for Excellence in Molecular Diagnostics
Defining Functional High-Risk Multiple Myeloma in the Era of Quadruplet Therapy and Autologous Stem Cell Transplant
Long-Term Outcomes With SABR in Primary Kidney Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo